Paul Hastings LLP
We only have limited information for this firm. Consider the following firms which have provided more information:
Strategically focused on the handling of late-stage buyout deals, Paul Hastings LLP’s China private equity offering is renowned for handling the full range of investment transactions, with particular strength in the TMT, entertainment, real estate and healthcare sectors. The firm boasts an impressive and diverse client roster, handling significant transactions for the likes of Ping An, GenScript Biotech and Alpha Investment Partners. David Wang has established a strong reputation for M&A and PE transactions in the technology sector, splitting his time between Beijing and Shanghai. As does Jia Yan, whose expertise in Hong Kong and US IPOs, fund formation and other PE investments is well known in the Chinese market. Beijing-based Meka Meng specialises in a wide array of investment fund work, while in Hong Kong, Fang Pei and Vivian Lam remain key contacts.
Legal 500 Editorial commentary
Key clients
- CDH Investments
- Ping An Group
Abbreviated data is displayed for this firm.
Work highlights
- Advised GenScript Biotech Corporation and its subsidiary Probio Technology Limited in Probio’s Series C financing with investments from Legend Capital, Highlight Capital, Hillhouse (Probio’s Series A investor) and other institutional investors.
- Assisted Bain Gamma with successfully closing its $90m Series A financing.
Abbreviated data is displayed for this firm.